University of Washington Arboviral Research Network (UWARN)

华盛顿大学虫媒病毒研究网络 (UWARN)

• 批准号: 10687434
• 负责人: Michael Gale
• 金额: $ 116.6万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-16 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10687434
• 关键词: Acute; Address; Administrative Coordination; Alphavirus; Animals; Antibodies; Arbovirus Infections; Arboviruses; Area; Arthropod Vectors; Back; Bacteriology; Binding; Biological Assay; Biological Markers; Blood; Body Fluids; Brazil; Cell Separation; Chikungunya virus; Clinical; Clinical Management; Clinical Trials; Collaborations; Collection; Congo; Containment; Data; Dengue; Dengue Infection; Dengue Virus; Detection; Development; Diagnosis; Diagnostic; Diagnostic Reagent; Disease; Emergency Situation; Emerging Communicable Diseases; Engineering; Enzyme-Linked Immunosorbent Assay; Epitopes; Far East; Fever; Flavivirus; Fluorescence; Freezing; Future; Genomic approach; Human; Immune response; Immune system; Immunoglobulin G; Individual; Infection; Infectious Diseases Research; Innate Immune Response; Innate Immune System; Institutes; Institution; International; Intervention; Investigation; Japanese Encephalitis; Knowledge; Laboratories; Laboratory Research; Lead; Light; Logistics; Measurement; Metagenomics; Microcephaly; Molecular; Monitor; Monoclonal Antibodies; Natural Immunity; Oropouche virus; Orthobunyavirus; Outcome; Pakistan; Parasitic infection; Pathogenesis; Pathway interactions; Patients; Population; Prevalence; Process; Production; Protein Engineering; Proteins; Readiness; Reagent; Research; Resources; Rift Valley Fever; Risk; Sampling; Senegal; Sensitivity and Specificity; Serology; Seroprevalences; Site; South Africa; South America; Specimen; Statistical Data Interpretation; System; Taiwan; Technology; Technology Transfer; Testing; The science of Mycology; Therapeutic; Time; Universities; Vaccines; Variant; Veterinarians; Viral; Viral Antibodies; Viral Hemorrhagic Fevers; Viral Load result; Virus; Virus Diseases; Washington; Yellow Fever; ZIKA; Zika Virus; antagonist; arthropod-borne; base; biobank; candidate marker; chikungunya; cohort; cross reactivity; data management; design; experience; global health; global health emergency; human monoclonal antibodies; improved; improved outcome; innovation; neutralizing antibody; neutralizing monoclonal antibodies; next generation sequencing; novel; novel diagnostics; novel strategies; pandemic disease; pandemic preparedness; pathogen; pathogenic virus; point of care; population based; prospective; severe dengue; therapeutic target; transcriptomics; viral detection; virology; virus host interaction; Acute; Address; Administrative Coordination; Alphavirus; Animals; Antibodies; Arbovirus Infections; Arboviruses; Area; Arthropod Vectors; Back; Bacteriology; Binding; Biological Assay; Biological Markers; Blood; Body Fluids; Brazil; Cell Separation; Chikungunya virus; Clinical; Clinical Management; Clinical Trials; Collaborations; Collection; Congo; Containment; Data; Dengue; Dengue Infection; Dengue Virus; Detection; Development; Diagnosis; Diagnostic; Diagnostic Reagent; Disease; Emergency Situation; Emerging Communicable Diseases; Engineering; Enzyme-Linked Immunosorbent Assay; Epitopes; Far East; Fever; Flavivirus; Fluorescence; Freezing; Future; Genomic approach; Human; Immune response; Immune system; Immunoglobulin G; Individual; Infection; Infectious Diseases Research; Innate Immune Response; Innate Immune System; Institutes; Institution; International; Intervention; Investigation; Japanese Encephalitis; Knowledge; Laboratories; Laboratory Research; Lead; Light; Logistics; Measurement; Metagenomics; Microcephaly; Molecular; Monitor; Monoclonal Antibodies; Natural Immunity; Oropouche virus; Orthobunyavirus; Outcome; Pakistan; Parasitic infection; Pathogenesis; Pathway interactions; Patients; Population; Prevalence; Process; Production; Protein Engineering; Proteins; Readiness; Reagent; Research; Resources; Rift Valley Fever; Risk; Sampling; Senegal; Sensitivity and Specificity; Serology; Seroprevalences; Site; South Africa; South America; Specimen; Statistical Data Interpretation; System; Taiwan; Technology; Technology Transfer; Testing; The science of Mycology; Therapeutic; Time; Universities; Vaccines; Variant; Veterinarians; Viral; Viral Antibodies; Viral Hemorrhagic Fevers; Viral Load result; Virus; Virus Diseases; Washington; Yellow Fever; ZIKA; Zika Virus; antagonist; arthropod-borne; base; biobank; candidate marker; chikungunya; cohort; cross reactivity; data management; design; experience; global health; global health emergency; human monoclonal antibodies; improved; improved outcome; innovation; neutralizing antibody; neutralizing monoclonal antibodies; next generation sequencing; novel; novel diagnostics; novel strategies; pandemic disease; pandemic preparedness; pathogen; pathogenic virus; point of care; population based; prospective; severe dengue; therapeutic target; transcriptomics; viral detection; virology; virus host interaction

Abstract: University of Washington Arboviral Research Network (UWARN) The University of Washington Arboviral Research Network (UWARN) will address emerging and re-emerging infectious diseases by carrying out research on arboviruses that include current high burden pathogens including dengue, chikungunya, and Zika viruses. Arboviruses also include emerging and re-emerging viruses such as Mayaro, Una, Usutu, Japanese encephalitis, yellow fever, Crimean-Congo hemorrhagic fever, and Oropouche viruses. UWARN will leverage the UW Metacenter for Pandemic Disease Preparedness and strong research laboratory partners in Brazil, Senegal, South Africa, Pakistan and Taiwan as well as the UW Department of Global Health global reach in capacity building. The UWARN international Collaborating Partners have institution-based and population-based cohorts in place to carry out the planned research and monitor for new virus emergence. The proposed UWARN research will create new human viral-neutralizing monoclonal antibodies (Hu-nMabs) that can be used as therapeutics or diagnostics. UWARN research will also create new diagnostics, created ab initio by the Institute for Protein Design, as artificial proteins that release light when antibodies to virus are present in body fluids. Finally, UWARN research will generate an understanding of how viruses manipulate the human innate immune system, and this information will be used to design biomarkers to predict severe disease as well as to suggest host-directed therapies that could lead to better outcomes after arboviral infection. The proposed technologies are generic and could be rapidly adapted to any future emerging arbovirus threat. UWARN collaborators span virology, bacteriology, mycology, and parasitic infections, such that UWARN can respond to diverse emerging infectious diseases threats. UWARN international laboratories have advanced capabilities including biorepositories with generator-power backed-up -80C freezers, next-generation sequencing (NGS) capabilities, fluorescence cell sorting, and BSL-3 containment facilities. UWARN cohorts have biobanked samples taken from individuals during acute febrile illnesses, with known and unknown arboviral diseases, and partnership sites are poised for prospective collection of population and facility–based samples. UWARN labs will use metagenomic NGS to detect novel viral emergence in affiliated cohorts. UWARN Partners have collaborating entomologists and veterinarians to sample arthropod vectors and animal reservoirs as needed. Additional innovative capacity included the Brazil UWARN partner’s mobile van with on board NGS capability for real-time, on-site viral sequencing and sampling to viral identification in less than 18 hrs. A second partner, IRESSEF in Senegal, plans to set up a similar mobile vehicle for viral sampling and sequencing in Senegal and the Brazil group will collaborate with IRESSEF on technology transfer and best practices. UWARN partners will serve as a resource to other Emerging Infectious Diseases Research Centers (EIDRC) providing expertise in monoclonal antibodies, protein design, and host directed therapies.

摘要：华盛顿大学arboviral研究网络（UWARN） 华盛顿大学arboviral研究网络（UWARN）将解决新兴和重新出现 通过对包括当前高烧伤病原体在内的弧菌病毒进行研究，包括传染病 登革热，基孔肯雅和寨卡病毒。 arbovirus还包括新兴和重新出现的病毒，例如 Mayaro，una，usutu，日本脑炎，黄热病，克里米亚 - 隆戈出血热和Oropouche 病毒。 Uwarn将利用UW Metacenter进行大流行疾病的准备和强有力的研究 巴西，塞内加尔，南非，巴基斯坦和台湾的实验室合作伙伴以及UW部门 全球卫生全球能力建设中的影响力。 Uwarn International合作伙伴有 基于机构的和基于人群的同伙进行了计划的研究，并监视了新的 病毒出现。拟议的UWARN研究将创建新的人类病毒中和单克隆 可以用作治疗或诊断的抗体（HU-NMAB）。 Uwarn研究也将创建新的 诊断，由蛋白质设计研究所创建的诊断，作为人造蛋白质，释放光 体液中存在于病毒的抗体。最后，Uwarn研究将对 病毒操纵人类的免疫系统，这些信息将用于设计生物标志物 预测严重疾病，并建议宿主指导的疗法，这些疗法可能会导致更好的结果 arboviral感染。拟议的技术是通用的，可以迅速适应未来的任何新兴 arbovirus威胁。 Uwarn合作者涵盖病毒学，细菌，真菌学和寄生虫感染，以至于 Uwarn可以应对新兴疾病的威胁。 Uwarn国际实验室有 高级功能，包括带有发电机支持-80C冰柜的生物震动剂，下一代 测序（NGS）功能，荧光细胞分选和BSL-3遏制设施。 Uwarn队列有 在急性发热疾病期间，从个体中采集的生物循环样本，已知和未知的arboviral 疾病和伙伴关系现场被毒害，以收集人口和设施的样本。 Uwarn Labs将使用宏基因组NGS来检测会员队列中的新病毒出现。 Uwarn合作伙伴 让昆虫学家和兽医合作采样节肢动物媒介和动物水库作为 需要。额外的创新能力包括巴西UWARN合作伙伴的移动面包车，并与NGS一起使用 实时的，现场病毒测序的第二个容量，并在不到18小时的时间内进行病毒鉴定。 塞内加尔的IRESSEF合作伙伴计划建立类似的移动车辆以进行病毒采样和测序 塞内加尔和巴西集团将与IRESSEF合作就技术转移和最佳实践。 uwarn 合作伙伴将作为其他新兴传染病研究中心（EIDRC）提供的资源 单克隆抗体，蛋白质设计和宿主定向疗法方面的专业知识。